Shree Ganesh Remedies Limited (SGRL) fundamentals
Shree Ganesh Remedies Limited is a listed company, part of the Pharmaceuticals sector, listed on the NSE as SGRL (ISIN INE414Y01015). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Shree Ganesh Remedies Limited does
Shree Ganesh Remedies Limited is an India-based company, which is engaged in the business of bulk drug intermediates. The Company's products include intermediates by active pharmaceutical ingredient (API), and fine and specialty chemicals. Its human health API intermediates include antipsychotic, antidepression, oncology, diabetic, and diuretic. Its specialty & fine chemicals include aroma & health industry, agro-industry, polymer industry, and electronics industry. Its veterinary API intermediates include feed additives, antiparasitic, and anti-inflammatory. Its anti-arrhythmic API intermediates include amiodarone intermediates, dronedarone intermediates, and mesalazine intermediates. Its anti-cancer API intermediates include cabozantinib intermediates, gefitinib intermediates, olaparib intermediates, and raloxifene intermediates. Its anti-parasitic API intermediates include flubendazole intermediates, nitazoxanide intermediates, and praziquantel intermediates.
Valuation and market data
| Last close | ₹656.05 |
|---|---|
| Market capitalisation | ₹842 crore |
| Enterprise value | ₹852 crore |
| P/E (TTM) | 47.44 |
| Price to book | 5.17 |
| Price to sales (TTM) | 4.75 |
| Book value per share | ₹126.90 |
| Dividend yield | 0.00% |
| Sector | Pharmaceuticals |
| Industry | — |
| Listed since | Mon Aug 17 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹112 crore | ₹24 crore | ₹18 crore | 13.83 |
| Mar 2025 | ₹112 crore | ₹31 crore | ₹23 crore | 17.96 |
| Mar 2024 | ₹129 crore | ₹38 crore | ₹28 crore | 22.34 |
| Mar 2021 | ₹51 crore | ₹13 crore | ₹10 crore | 0.00 |
| Mar 2020 | ₹68 crore | ₹14 crore | ₹10 crore | 11.67 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 72.8% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.5% |
| Retail and others | 26.6% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.